Chronic myeloid leukaemia Second and Third line initial PBS authority application Supporting information form (PB122)

You must lodge this form for a patient starting second or third line initial PBS subsidised treatment with a tyrosine kinase inhibitor (TKI agent) for any phase of chronic myeloid leukaemia and who has failed an adequate trial of a first or second-line TKI agent treatment.

 

Page last updated: 13 July 2016

This information was printed Wednesday 28 September 2016 from humanservices.gov.au/health-professionals/forms/pb122 It may not include all of the relevant information on this topic. Please consider any relevant site notices at humanservices.gov.au/siteinformation when using this material.